Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France

<table class="figure-group"><tr class="fig-image" id="a"><td><object data="https://static.hindawi.com/articles/ah/volume-2019/4625787/figures/4625787.fig.004a.svgz" name="4625787.fig.004a" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(a) </b>Progression-free survival</td></tr><tr class="fig-image" id="b"><td><object data="https://static.hindawi.com/articles/ah/volume-2019/4625787/figures/4625787.fig.004b.svgz" name="4625787.fig.004b" type="image/svg+xml"></object></td></tr><tr class="fig-caption"><td><b>(b) </b>Overall survival</td></tr></table>

<div>Progression-free and overall survival from initiation of third-line treatment.</div>

Advances in Hematology

fig4

Figure 4

Figure 4: Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France 

Figure 4 | Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France 